EWA
RIGL icon

EverSource Wealth Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

EverSource Wealth Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Sell
51
-167
-77% -$5.15K ﹤0.01% 3722
2026
Q1 		$5.89K Buy
218
+191
+707% +$6.42K ﹤0.01% 3186
2025
Q4 		$1.16K Buy
+27
New +$1.02K ﹤0.01% 3671
2025
Q2 		– Sell
-79
Closed -$1.42K – 4343
2025
Q1 		$1.42K Buy
79
+16
+25% +$325 ﹤0.01% 3087
2024
Q4 		$1.06K Hold
63
– – ﹤0.01% 2945
2024
Q3 		$1.02K Hold
63
– – ﹤0.01% 2725
2024
Q2 		$667 Buy
+63
New +$659 ﹤0.01% 2823
2022
Q2 		– Sell
-387
Closed -$11K – 1861
2022
Q1 		$11K Buy
+387
New +$10.5K ﹤0.01% 942

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EverSource Wealth Advisors's RIGL Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Rigel Pharmaceuticals (RIGL) stake by 77% in Q2 2026, selling an estimated $5.15K and leaving 51 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #3722.

EverSource Wealth Advisors first reported a position in RIGL in Q1 2022 and has held it in 8 quarters since. The position peaked at $11K in Q1 2022. 155 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • EverSource Wealth Advisors held 51 shares of Rigel Pharmaceuticals worth $2K as of Q2 2026.
  • EverSource Wealth Advisors sold 167 Rigel Pharmaceuticals shares in Q2 2026, an estimated $5.15K.
  • Rigel Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3722 holding.
  • EverSource Wealth Advisors first reported a position in Rigel Pharmaceuticals in Q1 2022 and has held it in 8 quarters since.
  • EverSource Wealth Advisors's Rigel Pharmaceuticals position peaked at $11K in Q1 2022.
  • 155 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.